Uploaded November 2022 | Updated September 2026, 1 week ago
Insilico Medicine has successfully created a unique approach to identifying potential therapeutic dual-purpose targets for aging and age-associated diseases with its PandaOmics software — an AI-enabled biological target discovery platform. The research supporting this approach was published in Aging (March 2022).
To read the full paper: aging-us.com/article/203960/text
To learn more about the study: insilico.com/dual-purposetherapeutictargetspredictedusingai
Follow us on LinkedIn: https://www.linkedin.com/showcase/pan...
For more information about the platform visit: insilico.com/pandaomics
Insilico Medicine has successfully created a unique approach to identifying potential therapeutic dual-purpose targets for aging and age-associated diseases with its PandaOmics software — an AI-enabled biological target discovery platform. The research supporting this approach was published in Aging (March 2022).
To read the full paper: aging-us.com/article/203960/text
To learn more about the study: insilico.com/dual-purposetherapeutictargetspredictedusingai
Follow us on LinkedIn: https://www.linkedin.com/showcase/pan...
For more information about the platform visit: insilico.com/pandaomics
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
